Skip to main content

MOPETT Trial (Multicenter Observational Study of Pulmonary Embolism Thrombolysis)-2013

 MOPETT trial (Multicenter Observational Study of Pulmonary Embolism Thrombolysis) was a randomized controlled trial that evaluated the efficacy and safety of low-dose thrombolysis in patients with acute intermediate-risk pulmonary embolism (PE). 

The trial included 121 patients who were randomly assigned to receive either low-dose alteplase (50 mg) or low-dose heparin plus placebo. 

The primary endpoint of the trial was the development of pulmonary hypertension at 28 months. The secondary endpoints were recurrent PE at 28 months and major bleeding events. 

The results of the trial showed that low-dose alteplase significantly reduced the risk of developing pulmonary hypertension at 28 months compared to low-dose heparin plus placebo (28% vs. 56%).

There was no significant difference between the two groups in the risk of recurrent PE or major bleeding events. 



The MOPETT trial provides evidence that low-dose thrombolysis is an effective and safe treatment option for patients with acute intermediate-risk PE.

Key findings of the MOPETT Trial included: 

1.    Reduced right ventricular strain: The trial showed that catheter-directed thrombolysis with alteplase significantly reduced right ventricular strain, which is a common complication of acute PE and can lead to poor outcomes. 

2.    Improved hemodynamics: Patients who received thrombolysis showed better improvement in their hemodynamic status compared to those treated with anticoagulation alone. 

3.    No significant difference in major bleeding events: The trial found that while thrombolysis increased the risk of minor bleeding events, there was no significant increase in major bleeding events when compared to anticoagulation therapy alone. 

4.    Suggested benefit for select patients: The results suggested that catheter-directed thrombolysis with alteplase may be particularly beneficial for a subset of patients with acute PE who have significant right ventricular strain and hemodynamic instability.

5.    The trial also suggests that low-dose thrombolysis may be particularly beneficial in preventing the development of pulmonary hypertension, a serious complication of PE. 

Here is a summary of the key findings of the MOPETT trial: Low-dose alteplase (50 mg) significantly reduced the risk of developing pulmonary hypertension at 28 months compared to low-dose heparin plus placebo (28% vs. 56%). There was no significant difference between the two groups in the risk of recurrent PE or major bleeding events. Low-dose thrombolysis is an effective and safe treatment option for patients with acute intermediate-risk PE. Low-dose thrombolysis may be particularly beneficial in preventing the development of pulmonary hypertension. 

It is important to note that the MOPETT trial was a small study, and further research is needed to confirm these findings. However, the results of the MOPETT trial provide promising evidence that low-dose thrombolysis may be a valuable treatment option for patients with acute intermediate-risk PE.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

CRASH-3 TRIAL (Tranexamic Acid in Head Injury)

 
Post a Comment
Read more

Lignocaine Associated Systemic Toxicity (LAST)

  Lidocaine Associated Systemic Toxicity (LAST) Lidocaine Associated Systemic Toxicity (LAST) is a potentially life-threatening condition that occurs due to the excessive absorption of local anesthetics, particularly lidocaine, into the systemic circulation. LAST can result from inadvertent intravascular injection, overdose, or rapid absorption from highly vascularized areas.   Pathophysiology: Lidocaine, like other local anesthetics, works by blocking sodium channels, inhibiting the initiation and propagation of nerve impulses. However, when systemic levels of lidocaine become excessively high, these sodium channels are blocked in vital organs such as the heart and brain, leading to serious complications. Clinical Presentation: LAST can manifest with a variety of symptoms that often progress through two stages: Neurological Symptoms : Early signs include circumoral numbness, metallic taste, tinnitus, and dizziness. As toxicity increases, more severe symptoms such as seizures,...
Post a Comment
Read more

BLUNT TRAUMA TO EYE VARIOUS FINDINGS

Blunt trauma to the eye can result in a wide range of findings and injuries, depending on the force and direction of the impact. The Trauma can be due to Direct Injury Contre-coup Injury Shearing forces and shock waves. The eye is a delicate organ with several components, and trauma can result into open or closed globe injuries. Following are some of the findings and injuries commonly associated with blunt trauma to different components of the eye:         Eyelids and Surrounding Tissues: ü   Contusions and bruising of the eyelids and periorbital area. May give an appearance of Raccoon Eyes. ü   Lacerations or cuts on the eyelids. ü   Swelling and edema of the eyelids.         Conjunctiva: ü   Subconjunctival hemorrhage, which appears as redness on the white part of the eye. ü   Chemosis, which is swelling of the conjunctiva.         Cornea: ü ...
Post a Comment
Read more